CordenPharma, a leading global Contract Development and Manufacturing Organization (CDMO), today announces that it has entered into an agreement to acquire AmbioPharm, a U.S.- headquartered peptide API CDMO. Adding complementary peptide API capabilities: With its two sites in South Carolina (USA) and Shanghai (China), AmbioPharm adds differentiated peptide manufacturing capabilities to CordenPharma’s existing Peptides Platform and expertise. Once combined, these will include advanced linear and fragment-based peptide approaches supported by flexible... READ MORE CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity Eli Lilly Acquires Engage Bio in $202 Million Deal Engage Biologics, a biotechnology company advancing novel non-viral DNA delivery systems, announced that it had been acquired by Eli Lilly & Company on May 20th, 2026. According to a company press release, Lilly will pay up to $202 million in cash, including upfront and milestone payments, for the acquisition. Additional financial details were not disclosed in the announcement. Engage’s Tethosome platform is a novel non-viral DNA delivery system that combines engineered DNA payloads with lipid nanoparticle delivery and a proprietary mRNA-encoded technology... READ MORE
RkJQdWJsaXNoZXIy MjY2OTA4MA==